Aufman Associates’s NeoGenomics NEO Stock Holding History

Aufman Associates’s Portfolio NEO Stock Details NEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-3,840	Closed	-$207K	–	47
2020 Q4	$207K	Buy	+3,840	New	+$174K	0.19%	41

Other funds holding NEO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

KFO

Kopp Family Office Bloomington, Minnesota $163M AUM 22.57% 1-Year Est. Return

Aufman Associates's NEO Position: Q1 2021 in Review

Aufman Associates sold out of NeoGenomics (NEO) in Q1 2021, closing a stake of 3,840 shares — an estimated $207K sold.

Aufman Associates first reported a position in NEO in Q4 2020 and held it in 1 quarter. The position peaked at $207K in Q4 2020. 332 funds tracked by Wall St. Rank hold NEO as of Q1 2021.

Aufman Associates reported no remaining NeoGenomics position as of Q1 2021 after selling out during the quarter.
Aufman Associates sold 3,840 NeoGenomics shares in Q1 2021, an estimated $207K.
Aufman Associates first reported a position in NeoGenomics in Q4 2020 and held it in 1 quarter.
Aufman Associates's NeoGenomics position peaked at $207K in Q4 2020.
332 funds tracked by Wall St. Rank held NeoGenomics as of Q1 2021.

Based on Aufman Associates's 13F filing for Q1 2021, filed 17 May 2021.